Snapshot

Bioprocessing and CDMOs (Contract Development and Manufacturing Organizations) form the physical production layer that turns drug molecules into finished injectable medicines. The unit of capacity is bioreactor volume in liters — stainless-steel or single-use vessels where living cells grow and secrete therapeutic proteins (mostly monoclonal antibodies, but increasingly cell therapies, gene therapies, and antibody-drug conjugates). Global installed mammalian cell-culture capacity reached roughly 6.7 million liters in 2024, up from ~2.2 million liters in 2007 (6.6% CAGR over 17 years, BioPlan Associates 21st Annual Survey via BioProcess International). Current annual volumetric demand is around 2.5 million liters (~47,500 kg of biologic drug substance). The global biologics market was $444 billion in 2024 (monoclonal antibodies = 57% share), growing at ~9.8% CAGR toward $1.1 trillion by 2034 est. (Statifacts). The broader CDMO market (biologics + small molecule outsourced manufacturing) was ~$157 billion in 2024, projected to ~$315 billion by 2034 at 7.2% CAGR est. (BCC Research/Precedence Research).

A single 2,000 L bioreactor can satisfy annual demand for roughly 50% of marketed biologics. Two parallel 2,000 L units cover ~62%. Only ~20% of commercial biologics need bioreactors above 10,000 L. The bottleneck is not raw volume — it is qualified capacity in the right modality, at the right scale, with regulatory approval for the target market.

The product & how money is made

What the industry sells

The bioprocessing supply chain has three layers, each with a different revenue model:

• CDMOs (Catalent/Novo Holdings, Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher/Patheon) — manufacture finished biologic drug product under contract. Revenue comes from batch fees: a client pays per manufacturing campaign (process development, clinical-scale batches, then commercial-scale production). Contracts typically span years and include milestones tied to clinical trial phases and regulatory approvals. The largest CDMOs operate stainless-steel bioreactors at 10,000–25,000 L and single-use bioreactors at 2,000–6,000 L.
• Bioprocessing equipment & consumables (Repligen, Sartorius, Danaher/Cytiva, MilliporeSigma) — sell the hardware and disposable components used inside every bioreactor facility: filtration membranes, chromatography resins (columns that separate and purify proteins), process analytics sensors, and single-use bags and tubing. Revenue is recurring consumables: each batch of drug consumes filters, resins, and bags that must be replaced. Equipment (capital hardware) is the smaller, lumpier portion.
• Primary packaging & delivery (West Pharmaceutical Services) — make the vials, stoppers, syringe barrels, cartridge systems, and self-injection devices that contain and deliver the finished biologic to the patient. Revenue is per-unit component sales: every dose of every injectable drug needs a container/closure system. WST's "High-Value Products" (FluroTec-coated stoppers, NovaPure components) carry higher margins because they reduce particulate contamination risk — a compliance requirement for biologics.

How cash flows through the chain

A pharma company developing a biologic drug pays at each stage: process development fees ($1–5M est.), clinical manufacturing ($5–50M+ depending on trial size est.), and commercial manufacturing (ongoing, often $50–200M+ per year for a blockbuster drug est.). The CDMO captures batch fees. Equipment and consumables suppliers capture per-batch disposable revenue from both CDMOs and pharma companies that manufacture in-house. The packaging supplier captures per-dose revenue once the drug reaches commercial production.

Demand

Contracted / observable

• WuXi Biologics backlog: $18.5 billion total as of December 31, 2024 ($10.5B services + $8.0B potential milestones), with $3.7 billion executable within 3 years. WuXi supported 817 integrated client projects including 21 commercial manufacturing programs (ex-COVID), completed 16 PPQ runs (process performance qualification — the final manufacturing validation before commercial sale) in 2024, and has 24 scheduled for 2025. contracted
• Repligen FY2025 revenue: $738M (+16% YoY organic ex-COVID), with FY2026 guidance of $810–840M (+10–14%). Repligen sells into every bioreactor facility, so its organic growth rate is a direct proxy for global bioprocessing throughput. Q4 2025 growth led by Analytics and Proteins product lines. contracted
• WST FY2025 revenue: $3.07B (+6.3% YoY). Proprietary Products segment = 81% of revenue (~$2.49B), driven by biologics-related High-Value Products. Largest single customer = 15.8% of consolidated sales (~$486M). contracted
• TMO FY2025 Lab Products & Biopharma Services segment: $24.0B revenue (+3.5% YoY). The CDMO (Patheon) sub-business within this segment is not separately disclosed. contracted

Forecast demand drivers

• Biologics market growth: global biologics revenue projected from $444B (2024) to ~$1.1T (2034) at 9.8% CAGR (Statifacts). Monoclonal antibodies dominate today (57% share); cell and gene therapies, ADCs (antibody-drug conjugates), and bispecific antibodies are the fastest-growing categories. est.
• Volumetric demand projected to double by 2028, from ~2.5M L to ~5M L of annual bioreactor demand (BioPlan/BioProcess International). est.
• Outsourcing shift: CDMOs held 8% of installed capacity in 2007, 20% in 2020, 28% in 2024, and are projected at 38% by 2028. est.
• Biosimilar wave: over $100B in originator biologic drug revenue faces patent expiry through 2030. Each biosimilar requires its own validated manufacturing process, often at a different CDMO. est.
• AI-accelerated drug discovery: as AI compresses the timeline from target identification to IND filing, more candidates enter clinical development earlier, each requiring GMP manufacturing capacity from Phase 2 onward.

BioPlan 21st Annual Survey (2024); BioProcess International supply/demand analysis; Statifacts biologics report; WuXi Biologics 2024 AR; Repligen FY2025 earnings; WST FY2025 earnings; TMO FY2025 press release.

Supply

Installed capacity (2024)

Samsung Biologics press releases; Lonza/Pharma Manufacturing; DCAT report; BioProcess Insider; Fujifilm Diosynth press releases; BioPlan 21st Annual Survey.

Capacity under construction (2024–2030)

Over 2.2 million liters of additional mammalian capacity is projected to come online by 2028, bringing the global total to roughly 8.9 million liters est. (BioProcess International). Major disclosed projects:

• Samsung Bio Campus II (Plants 5–8): each 180,000 L. KRW 7.5T (~$6B) total. Plant 5 done 2025; Plants 6–8 through ~2032. Target: 1.3M L total company-wide.
• Fujifilm Holly Springs expansion: 8 additional 20,000 L bioreactors (+160,000 L) by 2028. Additional $1.2B on top of original $2B.
• Lonza Vacaville upgrade: CHF 500M ($554M) modernization of 332,000 L acquired from Genentech.
• Lotte Biologics: 360,000 L across 3 plants in Songdo. $3B. Target: 2030.
• AGC Biologics Yokohama: JPY 50B (~$350M). Operational 2026.
• MilliporeSigma Daejeon: >EUR 300M (~$326M). Bioprocessing production center. By 2028.

Aggregate disclosed CDMO facility investment across all players exceeds $17 billion in announced projects (DCAT report). est.

Bottleneck

• Regulatory qualification: a new bioreactor does not produce saleable drug until it passes GMP (Good Manufacturing Practice) inspection by the FDA, EMA, or PMDA. This takes 12–24 months after physical construction is complete.
• Modality mismatch: most installed capacity is optimized for large-scale monoclonal antibody production in 10,000–25,000 L stainless steel. Cell therapies, gene therapies (viral vectors), and ADCs require smaller, specialized cleanroom suites with separate air handling. Viral vector GMP slot wait times run 12–18 months est..
• Single-use scale ceiling: single-use bioreactors have reached ~90% adoption at the 2,000 L scale but max out at ~6,000 L today. Drugs requiring larger volumes need stainless-steel facilities (3–5 years to build, $500M+).
• Geopolitical risk: the US BIOSECURE Act, if enacted, would restrict pharma companies from using Chinese CDMOs (WuXi Biologics, WuXi AppTec). WuXi's $18.5B backlog would need to be reshored to Western CDMOs.

The gap

On raw liters, supply exceeds demand: ~6.7M L installed vs. ~2.5M L of annual volumetric demand (2024). Demand is projected to double to ~5M L by 2028, while capacity grows to ~8.9M L — the aggregate surplus persists at ~1.8x coverage est..

The tightness is in specialty modalities: cell therapy manufacturing suites, viral vector production, and ADC conjugation/fill-finish lines. Wait times for viral vector GMP manufacturing slots run 12–18 months at major CDMOs est..

Pricing direction by sub-segment:

• Large-scale mAb CDMO services: flat to modestly declining in real terms, driven by Samsung, Fujifilm, and Lotte capacity additions. est.
• Cell & gene therapy manufacturing: stable to rising, driven by scarcity of qualified suites. est.
• Bioprocessing consumables (RGEN's market): stable with modest annual increases. Revalidation required when changing filter or resin vendor mid-production. est.
• Injectable packaging components (WST's market): stable to rising, driven by mix shift toward higher-value products (NovaPure, FluroTec) at 2–3x the price of standard components. est.

The players

Catalent (CTLT) was acquired by Novo Holdings (investment arm of the Novo Nordisk Foundation) for $16.5 billion ($63.50/share, all cash) in December 2024. CTLT shares were delisted. Catalent continues operating as a private CDMO but is no longer available as a public equity. Its capacity now preferentially serves Novo Nordisk's pipeline.

WST FY2025 results (MarketBeat / 10-K); TMO FY2025 press release (ir.thermofisher.com); RGEN FY2025 earnings (StockTitan); stockanalysis.com; companiesmarketcap.com. Prices as of Jun 3, 2026.

The price of exposure

WST — West Pharmaceutical Services

Market cap $22.3B at ~$316/share. Trailing P/E: 42x. FY2025 net income: $494M. Operating cash flow: $755M, CapEx $286M, free cash flow ~$469M. EV/FCF: ~46x. Balance sheet: $791M cash, $203M debt = $588M net cash. WST repurchased $561M of stock in FY2024. Revenue grew 6.3% YoY but net income was flat ($494M vs $493M) due to higher tax rate (20.2% vs 18.4%) and gross margin still recovering (35.9% vs 38.3% in 2023). Proprietary Products gross margin: 40.5%. Contract-Manufactured gross margin: 16.5%. Largest customer is ~15.8% of sales (~$486M).

TMO — Thermo Fisher Scientific

Market cap $180B at ~$474/share. Trailing P/E: 26x. FY2025 revenue: $44.6B. GAAP net income: $6.70B. Lab Products & Biopharma Services = $24.0B (54% of total) but includes distribution, lab equipment, and non-CDMO services. Life Sciences Solutions = $10.4B (23%). The Patheon CDMO business is a subset of the largest segment and is not separately broken out. ~$30B debt, largely from acquisitions.

RGEN — Repligen

Market cap $6.9B at ~$122/share. Trailing P/E: 134x (GAAP); forward P/E: ~62x on FY2026 adjusted estimates. FY2025 GAAP net income: $49M. Adjusted EBITDA: $140M (19% margin). FY2026 guided revenue: $810–840M. Guided adjusted operating margin: 15.1–15.5% (expanding ~150 bps YoY). At midpoint guidance (~$825M revenue, ~$126M adj. operating income), adjusted EPS ~$1.97. Management flagged a "two-point gene therapy headwind" in FY2026 guidance. Minimal debt.

stockanalysis.com; companiesmarketcap.com (Jun 3, 2026); company filings.

What to deep-dive next

• WST customer concentration: the ~$486M largest customer (15.8% of sales) is likely a GLP-1 obesity/diabetes franchise (Novo Nordisk or Eli Lilly). What happens when GLP-1 competitors launch in different delivery formats (oral, patches)?
• RGEN margin trajectory: adjusted operating margin guided to expand ~150 bps/year. At what scale does RGEN reach 20%+ operating margins?
• BIOSECURE Act impact: if the US restricts pharma from using Chinese CDMOs, WuXi's $18.5B backlog ($3.7B near-term) would need reshoring. Who captures that — Lonza, Fujifilm, Samsung, Patheon?
• TMO Patheon isolation: can Patheon CDMO revenue be estimated from pre-acquisition Patheon financials (~$7B at acquisition in 2017, grown at segment rate)?
• Cell & gene therapy capacity map: viral vector and autologous cell therapy manufacturing is the genuinely scarce sub-segment. Catalent (now private) was the largest provider. Who fills that gap?
• Novo Holdings conflict: with Catalent now owned by the Novo Nordisk Foundation, does Catalent capacity get reserved for Novo Nordisk's pipeline? If so, net third-party CDMO supply decreases.

Sources & confidence